BioSpace News Archive

ALTO-300 was significantly more effective in major depressive disorder patients with a specific EEG biomarker than in those without, according to results from an Alto Neuroscience Phase IIa study.

The regulator placed a partial clinical hold on Roche’s fenebrutinib—being developed for relapsing MS—after two patients experienced elevated hepatic transaminase and bilirubin levels indicative of liver injury.

Ten of the anticipated assets have the potential to deliver $5 billion or more in peak year sales, while another 15 of the candidates have a $1 billion to $5 billion PYS potential, according to Johnson & Johnson.

The gene editing company is dropping two programs and favoring its next-generation assets CTX112 and CTX131, which it will continue to develop in oncology but will also test in autoimmune diseases.

In this third episode of Denatured’s series on AI in drug discovery, we discuss patient behavior and its influence on clinical trials and AI models with guests from GSK, IQVIA, Exelixis and DataHow.

Fueled partly by increasing lifespans and cancer incidence, the area’s worth is projected to soar to 13.67 billion by 2032, Precedence Research reports.

A combination of Roche’s investigational treatment with Ibrance and fulvestrant met its primary endpoint of progression-free survival in the first-line setting in treating PIK3CA-mutated breast cancer.

Genentech, a member of the Roche Group, announced positive results from the Phase III INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib and fulvestrant as a potential first-line treatment option for people with PIK3CA-mutated, hormone receptor -positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer.

RELIEF THERAPEUTICS Holding SA announced its intent to progressively transition from a direct marketing and sales infrastructure for its commercial-stage assets to a partnership-based model.

ANGLE plc is delighted to announce the launch of its Portrait®+ CTC staining kit at the San Antonio Breast Cancer Symposium.